VolitionRx Limited (VNRX)
0.49
-0.01 (-2.00%)
At close: Apr 17, 2025, 3:59 PM
0.48
-1.58%
Pre-market: Apr 21, 2025, 06:06 AM EDT
Company Description
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide.
It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.
The company operates Nucleosomics a technology platform for blood test.
VolitionRx Limited is based in Austin, Texas.
VolitionRx Limited

Country | United States |
IPO Date | Mar 2, 2012 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 85 |
CEO | Cameron Reynolds MBA |
Contact Details
Address: 13215 Bee Cave Parkway Austin, Texas United States | |
Website | https://www.volition.com |
Stock Details
Ticker Symbol | VNRX |
Exchange | AMEX |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000093314 |
CUSIP Number | 928661107 |
ISIN Number | US9286611077 |
Employer ID | 91-1949078 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Cameron Reynolds MBA | Founder, Chief Executive Officer, President & Director |
Dr. Salvatore Thomas Butera DVM | Chief Executive Officer of Volition Veterinary Diagnostics Development LLC |
Dr. Gaetan Michel Ph.D. | Chief Operating Officer |
Terig Hughes | Chief Financial Officer & Treasurer |
Dr. Andrew Retter MBBS | Chief Medical Officer |
Dr. Jacob Vincent Micallef MBA, Ph.D. | Chief Scientific Officer |
Gael Forterre M.B.A. | Chief Commercial Officer |
Louise Batchelor Day | Group Chief Marketing & Communications Officer |
Nicholas Plummer | Group General Counsel |
Sharon Ballesteros | U.S. Head of Quality & Development Process |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 16, 2025 | RW | Filing |
Apr 11, 2025 | S-3/A | [Amend] Filing |
Apr 07, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Apr 04, 2025 | 8-K | Current Report |
Apr 04, 2025 | S-1 | Filing |
Apr 04, 2025 | PRE 14A | Filing |
Mar 31, 2025 | 10-K | Annual Report |
Mar 31, 2025 | 8-K | Current Report |
Mar 27, 2025 | 4 | Filing |
Mar 27, 2025 | 4 | Filing |